Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway

Wang,Yan‑Gui; Yang,Tian‑Lun

doi:10.3892/etm.2015.2741

Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway

Authors:
- Yan‑Gui Wang
- Tian‑Lun Yang
View Affiliations

Affiliations: Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, P.R. China
Published online on: September 10, 2015 https://doi.org/10.3892/etm.2015.2741
Pages: 1777-1783
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have suggested that liraglutide could have a potential function in improving non‑alcoholic fatty liver disease (NAFLD); however, the underlying molecular mechanism remains unclear. The aim of the present study was to investigate the role of the AMP‑activated protein kinase (AMPK)/sterol regulatory element binding protein 1 (SREBP1) pathway in mediating the effect of liraglutide in reducing fatty degeneration in an in vitro NAFLD model. To resemble the NAFLD condition in vitro, L‑02 cells were treated with 0.5 mM free fatty acids (FFAs) for 24 h. Liraglutide could affect the expression of AMPKα1, phosphorylated AMPKα1 and SREBP1 in a dose‑dependent manner in FFA‑exposed L‑02 cells, as demonstrated by western blot analysis. The intracellular lipid accumulation was significantly decreased, as shown by oil red O staining. A significant decrease in the content of triglyceride and total cholesterol was observed when the FFA‑exposed L‑02 cells were incubated with liraglutide. In addition, the increased expression of liver‑type fatty acid‑binding protein in FFA‑exposed L‑02 cells was suppressed by liraglutide. These effects were reversed by compound C, an AMPK inhibitor. In conclusion, this study has demonstrated that liraglutide can reduce fatty degeneration induced by FFAs in hepatocytes, and this effect may be partially mediated by the AMPK/SREBP1 pathway.

View Figures

View References

1	Clark JM and Diehl AM: Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2:210–215. 2002. View Article : Google Scholar : PubMed/NCBI
2	Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
3	Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM and Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 40:1387–1395. 2004. View Article : Google Scholar : PubMed/NCBI
4	Vernon G, Baranova A and Younossi ZM: Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
5	Fan JG: An introduction of strategies for the management of nonalcoholic fatty liver disease (NAFLD) recommended by Asia Pacific Working Party on NAFLD. Zhonghua Gan Zang Bing Za Zhi. 15:552–553. 2007.(In Chinese). PubMed/NCBI
6	Petta S, Muratore C and Craxì A: Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis. 41:615–625. 2009. View Article : Google Scholar : PubMed/NCBI
7	Schwenger KJ and Allard JP: Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 20:1712–1723. 2014. View Article : Google Scholar : PubMed/NCBI
8	Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thøgersen H, Wilken M and Agersø H: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 43:1664–1669. 2000. View Article : Google Scholar : PubMed/NCBI
9	Gao H, Xu L, Li D, Guang L and Deng W: Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Xue Bao. 33:1661–1664. 2013.(In Chinese). PubMed/NCBI
10	Olaywi M, Bhatia T, Anand S and Singhal S: Novel anti-diabetic agents in non-alcoholic fatty liver disease: A mini-review. Hepatobiliary Pancreat Dis Int. 12:584–588. 2013. View Article : Google Scholar : PubMed/NCBI
11	Morrison A, Yan X, Tong C and Li J: Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol. 301:H895–H902. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Yang M, Ren H, Hu H, Boden G, Li L and Yang G: GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int. 33:794–804. 2013. View Article : Google Scholar : PubMed/NCBI
14	Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M and Blonde L: LEAD-6 Study Group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 374:39–47. 2009. View Article : Google Scholar : PubMed/NCBI
15	Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD and Colagiuri S: LEAD-1 SU Study Group: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 26:268–278. 2009. View Article : Google Scholar : PubMed/NCBI
16	Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M and Matthews DR: LEAD-2 Study Group: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 32:84–90. 2009. View Article : Google Scholar : PubMed/NCBI
17	Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M and Bode B: LEAD-3 (Mono) Study Group: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 373:473–481. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M and Blonde L: LEAD-4 Study Investigators: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 32:1224–1230. 2009. View Article : Google Scholar : PubMed/NCBI
19	Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM and Simó R: Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 52:2046–2055. 2009. View Article : Google Scholar : PubMed/NCBI
20	Özenirler S, Degertekin CK, Erkan G, Elbeğ Ş, Tuncer C, Kandilc U and Akyol G: Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 60:1095–1100. 2013.PubMed/NCBI
21	Higuchi N, Kato M, Tanaka M, Miyazaki M, Takao S, Kohjima M, Kotoh K, Enjoji M, Nakamuta M and Takayanagi R: Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease. Exp Ther Med. 2:1077–1081. 2011.PubMed/NCBI
22	Jung EJ, Kwon SW, Jung BH, Oh SH and Lee BH: Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. J Lipid Res. 52:1617–1625. 2011. View Article : Google Scholar : PubMed/NCBI
23	Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT and Newton RS: AMP-activated protein kinase: An emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 53:2490–2514. 2012. View Article : Google Scholar : PubMed/NCBI
24	Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL and Schulze A: SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224–236. 2008. View Article : Google Scholar : PubMed/NCBI
25	Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, Campbell-Thompson M, Crawford J, Shek EW, Scarpace PJ and Zolotukhin S: Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA. 100:14217–14222. 2003. View Article : Google Scholar : PubMed/NCBI
26	You M, Matsumoto M, Pacold CM, Cho WK and Crabb DW: The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 127:1798–1808. 2004. View Article : Google Scholar : PubMed/NCBI
27	Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R and Lefer DJ: Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 104:403–411. 2009. View Article : Google Scholar : PubMed/NCBI
28	Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, et al: Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase. Circulation. 119:2568–2577. 2009. View Article : Google Scholar : PubMed/NCBI